[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 647, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 60, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 2584615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "age": 48, "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher  Williams", "age": 44, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthias  Will M.D.", "age": 51, "title": "Senior VP & Chief Development Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 52, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 54, "title": "Senior VP, CFO & Principal Accounting Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 59, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 68, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 59, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.53, "open": 1.53, "dayLow": 1.485, "dayHigh": 1.54, "regularMarketPreviousClose": 1.53, "regularMarketOpen": 1.53, "regularMarketDayLow": 1.485, "regularMarketDayHigh": 1.54, "payoutRatio": 0.0, "beta": 1.762, "forwardPE": -2.1095889, "volume": 1150806, "regularMarketVolume": 1150806, "averageVolume": 1952525, "averageVolume10days": 2230790, "averageDailyVolume10Day": 2230790, "bid": 1.49, "ask": 1.59, "bidSize": 27, "askSize": 27, "marketCap": 409857120, "fiftyTwoWeekLow": 1.105, "fiftyTwoWeekHigh": 5.0, "priceToSalesTrailing12Months": 45.48409, "fiftyDayAverage": 1.4533, "twoHundredDayAverage": 2.683375, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 204427776, "profitMargins": 0.0, "floatShares": 134475932, "sharesOutstanding": 266140992, "sharesShort": 10449231, "sharesShortPriorMonth": 9910212, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.039300002, "heldPercentInsiders": 0.18086, "heldPercentInstitutions": 0.86307997, "shortRatio": 4.63, "shortPercentOfFloat": 0.0517, "impliedSharesOutstanding": 266140992, "bookValue": 1.394, "priceToBook": 1.1047345, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -238132992, "trailingEps": -0.88, "forwardEps": -0.73, "enterpriseToRevenue": 22.686, "enterpriseToEbitda": -0.789, "52WeekChange": -0.61691546, "SandP52WeekChange": 0.09362543, "quoteType": "EQUITY", "currentPrice": 1.54, "targetHighPrice": 14.0, "targetLowPrice": 5.7, "targetMeanPrice": 9.96667, "targetMedianPrice": 10.0, "recommendationMean": 1.22222, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 516575008, "totalCashPerShare": 1.941, "ebitda": -259082000, "totalDebt": 311144992, "quickRatio": 8.735, "currentRatio": 9.244, "totalRevenue": 9011000, "debtToEquity": 83.842, "revenuePerShare": 0.034, "returnOnAssets": -0.20275, "returnOnEquity": -0.49967998, "grossProfits": -146023008, "freeCashflow": -214390128, "operatingCashflow": -241322000, "revenueGrowth": -0.11, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -7.2630796, "financialCurrency": "USD", "symbol": "AUTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1748043339, "regularMarketTime": 1748030400, "exchange": "NMS", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "fiftyDayAverageChange": 0.08669996, "fiftyDayAverageChangePercent": 0.059657305, "twoHundredDayAverageChange": -1.1433749, "twoHundredDayAverageChangePercent": -0.42609584, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1952525, "fiftyTwoWeekLowChange": 0.43499994, "fiftyTwoWeekLowChangePercent": 0.3936651, "fiftyTwoWeekRange": "1.105 - 5.0", "fiftyTwoWeekHighChange": -3.46, "fiftyTwoWeekHighChangePercent": -0.69200003, "fiftyTwoWeekChangePercent": -61.691547, "earningsTimestamp": 1746702002, "earningsTimestampStart": 1754656200, "earningsTimestampEnd": 1755865800, "earningsCallTimestampStart": 1746707400, "earningsCallTimestampEnd": 1746707400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.88, "epsForward": -0.73, "epsCurrentYear": -0.93788, "priceEpsCurrentYear": -1.6420012, "regularMarketChangePercent": 0.6535942, "regularMarketPrice": 1.54, "messageBoardId": "finmb_562879769", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1529674200000, "postMarketChangePercent": -1.94805, "postMarketPrice": 1.51, "postMarketChange": -0.03, "regularMarketChange": 0.00999999, "regularMarketDayRange": "1.485 - 1.54", "marketState": "CLOSED", "displayName": "Autolus Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-24"}]